Trump’s huge tariffs on some drugmakers could end up backfiring
Drug Tariffs Could Put Pressure on Smaller Manufacturers
Qwenews.com – A new 100% tariff on selected patented pharmaceutical products and ingredients is set to take effect Tuesday, raising questions about whether the policy will expand US drug production or instead squeeze the companies least able to absorb the cost.
President Donald Trump has framed the tariffs as a way to bring more manufacturing back to the United States and reduce dependence on overseas production. Yet the companies most exposed are often small or midsize drugmakers with limited capital, limited manufacturing capacity and few practical options for relocating production quickly.
That creates a potential conflict with another stated administration objective: lowering the price of medicines. If affected manufacturers face substantially higher import costs, some may raise prices, reduce their product lines, seek acquisitions or leave certain markets altogether.
Many Major Drugmakers Avoid the Full Rate
The new policy includes broad exemptions and lower tariff levels that significantly narrow the group facing the 100% rate. Large pharmaceutical companies that signed “Most Favored Nation” agreements are excluded from the highest levy. In exchange, those companies have committed to increase domestic manufacturing and offer lower prices through Medicaid and TrumpRx, the administration’s direct-to-consumer clearinghouse.
Those larger manufacturers produce most brand-name medicines. Generic drugs, orphan medicines for rare conditions and many specialty products are also mostly outside the tariff’s reach.
Trade arrangements further limit the policy. Patented pharmaceuticals imported from the European Union, Switzerland, Japan and South Korea will generally face a 15% tariff because of existing bilateral agreements. Products from the United Kingdom are exempt, while companies with agreements to increase US manufacturing will be charged a 20% rate.
As a result, only a relatively small portion of pharmaceutical producers and products will be subject to the full 100% tariff. Still, that smaller group could include companies that supply medicines for conditions not served by the industry’s biggest players.
Contract Manufacturing Is a Major Constraint
A preliminary Brookings Institution review identified more than 100 drugmakers with at least one nonexempt medicine. Many of those companies do not operate manufacturing plants of their own and instead rely on contract manufacturers.
Building new facilities or moving production to the United States is not a simple short-term response. Domestic contract manufacturing capacity is highly competitive, and securing it can be expensive—particularly for businesses without the financial reserves of multinational pharmaceutical companies.
Marta Wosinska, a senior fellow at Brookings, described the competition for US contract manufacturing space as unusually intense.
“Their pockets are not as deep,”
For smaller firms, the tariff could therefore become a financial problem rather than an incentive to build domestic production. Companies unable to obtain White House agreements or negotiate viable manufacturing arrangements may be pushed to sell to larger rivals, Wosinska said.
Potential Consequences for Patients and Innovation
Patients could feel the effects most sharply when they depend on treatments produced by smaller manufacturers. These companies may serve narrower patient populations or focus on medicines that do not attract the same attention as major blockbuster drugs.
Mollie Sitkowski, an international trade lawyer with Faegre Drinker, said prices for affected medicines are likely to increase. She also expects fewer new drugs to reach the market in the years ahead if developers redirect money away from research, clinical work and product launches to cover tariff-related costs.
The concern extends beyond immediate pricing. Smaller biotechnology and pharmaceutical companies often play an important role in early-stage drug discovery, including work on therapies that larger companies may later license, acquire or help commercialize. A policy that weakens these firms could reduce the range of projects able to move forward.
The Biotechnology Innovation Organization, which represents small and midsize drugmakers, warned the Commerce Department earlier this month that tariffs aimed at US innovators could undermine the broader goal of strengthening the domestic industry.
“The reality is that tariffs on America’s medicines will raise costs, impede domestic manufacturing, and divert scarce resources away from research and development critical to maintaining American biotech leadership,”
John Crowley, BIO’s chief executive, wrote in the organization’s message to the department.
The tariff plan highlights a difficult policy balance. Encouraging US production may be politically attractive and could reduce certain supply-chain vulnerabilities over time. But pharmaceutical manufacturing requires specialized facilities, regulatory approvals, technical expertise and reliable access to ingredients. Those requirements make rapid shifts far more difficult than moving production of many consumer goods.
Whether the tariffs produce new US investment or greater consolidation will depend heavily on how companies use available exemptions, whether they can access domestic manufacturing capacity and whether the administration grants additional agreements. For patients, the immediate question is simpler: whether the policy leaves more treatment options available at prices they can afford.
Related Reading
Frequently Asked Questions
What is Trump s huge tariffs on some?Trump s huge tariffs on some is the main topic of this guide. The article explains the context, practical details, and next steps readers should understand.
Why does Trump s huge tariffs on some matter?Trump s huge tariffs on some matters because readers are looking for a useful answer, not just a short summary. Good content should match search intent and help them decide what to do next.